Canada · Delayed Price · Currency is CAD Lassonde Industries Earnings Call Transcripts
Fiscal Year 2025
-
Record sales and profitability were achieved in 2025, with strong margin expansion and market share gains across all divisions. The outlook for 2026 targets CAD 3 billion in sales, supported by innovation, disciplined pricing, and capacity investments.
-
Q3 2025 saw 8.3% sales growth and a 23% rise in operating profit, driven by pricing and improved private label mix. Full-year sales are expected to rise over 10%, with commodity volatility and trade uncertainty as key risks. Leverage and cash flow improved.
-
Record sales and profitability were achieved in 2024, driven by growth across all divisions and the acquisition of Summer Garden. Major investments in U.S. facilities and leadership changes support future expansion, while risks from commodity prices and trade remain closely monitored.
-
Sales grew 22.8% to CAD 700 million, driven by market share gains and the Summer Garden acquisition. Adjusted EBITDA rose 36%, and the company expects 10% sales growth in 2025, while remaining cautious amid commodity volatility and increased U.S. promotions.
Fiscal Year 2024
-
Record 2024 results with sales over CAD 2.6B and strong EBITDA growth, driven by U.S. volume gains, Canadian pricing, and the Summer Garden acquisition. 2025 outlook targets 10% sales growth, with margin recovery expected after Q1 cost pressures and continued investment in U.S. expansion.
-
Q3 2024 saw strong sales and profit growth, driven by volume gains, efficiency improvements, and the Summer Garden acquisition. Major U.S. investments and ongoing innovation support a positive outlook, despite commodity cost pressures and global trade uncertainties.
-
Q2 saw 7.8% sales growth and 21% higher operating profit, led by U.S. volume gains and efficiency improvements. The North Carolina expansion and Summer Garden acquisition support future growth, with 2024 sales guidance raised to mid- to high-single digits.
-
The acquisition nearly doubles specialty food presence and expands U.S. reach, adding premium and health-oriented brands with strong growth potential. The $235M deal is accretive to margins and EPS, with synergies and integration investments expected to drive further value.